# Subcutaneous Lidocaine For Cancer-Related Pain

> **NCT01384877** · PHASE2,PHASE3 · COMPLETED · sponsor: **British Columbia Cancer Agency** · enrollment: 33 (actual)

## Conditions studied

- Cancer-related Pain

## Interventions

- **DRUG:** Lidocaine
- **DRUG:** Placebo (D5W)

## Key facts

- **NCT ID:** NCT01384877
- **Lead sponsor:** British Columbia Cancer Agency
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2017-12
- **Final completion:** 2019-01
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2019-07-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01384877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01384877, "Subcutaneous Lidocaine For Cancer-Related Pain". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01384877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*